Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/259065
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity |
Autor: | Fresno, Carlos del; García-Arriaza, Juan CSIC ORCID ; Martínez-Cano, Sarai; Heras-Murillo, Ignacio; Jarit-Cabanillas, Aitor; Amores-Iniesta, Joaquín; Brandi, Paola; Dunphy, Gillian; Suay-Corredera, Carmen; Pricolo, Maria Rosaria; Vicente, Natalia; López-Perrote, Andrés CSIC ORCID; Cabezudo, Sofía CSIC ORCID; González-Corpas, Ana; Llorca, Óscar CSIC ORCID; Alegre-Cebollada, Jorge; Garaigorta, Urtzi ; Gastaminza, Pablo CSIC ORCID; Esteban, Mariano CSIC ORCID ; Sancho, David | Palabras clave: | Innate immunity Viral infections Polybacterial mucosal immunotherapy SARS-CoV-2 Vaccine immunogenicity |
Fecha de publicación: | 18-nov-2021 | Editor: | Frontiers Media | Citación: | Frontiers in Immunology 12: 748103 (2021) | Resumen: | COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal immunotherapy, based on a mixture of whole heat-inactivated bacteria, that has shown clinical efficacy against recurrent viral respiratory infections. Herein, we show that the prophylactic intranasal administration of this immunotherapy confers heterologous protection against SARS-CoV-2 infection in susceptible K18-hACE2 mice. Furthermore, in C57BL/6 mice, prophylactic administration of MV130 improves the immunogenicity of two different COVID-19 vaccine formulations targeting the SARS-CoV-2 spike (S) protein, inoculated either intramuscularly or intranasally. Independently of the vaccine candidate and vaccination route used, intranasal prophylaxis with MV130 boosted S-specific responses, including CD8+-T cell activation and the production of S-specific mucosal IgA antibodies. Therefore, the bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity. | Versión del editor: | https://doi.org/10.3389/fimmu.2021.748103 | URI: | http://hdl.handle.net/10261/259065 | DOI: | 10.3389/fimmu.2021.748103 | E-ISSN: | 1664-3224 |
Aparece en las colecciones: | (PTI Salud Global) Colección Especial COVID-19 (CNB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
fimmu-12-748103.pdf | 7,86 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
21
checked on 22-abr-2024
WEB OF SCIENCETM
Citations
17
checked on 29-feb-2024
Page view(s)
79
checked on 27-abr-2024
Download(s)
284
checked on 27-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons